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OPEN
ORIGINAL ARTICLE
Relationships between brain and body temperature, clinical and
imaging outcomes after ischemic stroke
Bartosz Karaszewski1,2,3, Trevor K Carpenter1,2, Ralph GR Thomas1,2, Paul A Armitage1,2, Georgina Katherine S Lymer1,2, Ian Marshall1,4,
Martin S Dennis2 and Joanna M Wardlaw1,2
Pyrexia soon after stroke is associated with severe stroke and poor functional outcome. Few studies have assessed brain
temperature after stroke in patients, so little is known of its associations with body temperature, stroke severity, or outcome. We
measured temperatures in ischemic and normal-appearing brain using 1H-magnetic resonance spectroscopy and its correlations
with body (tympanic) temperature measured four-hourly, infarct growth by 5 days, early neurologic (National Institute of Health
Stroke Scale, NIHSS) and late functional outcome (death or dependency). Among 40 patients (mean age 73 years, median NIHSS 7,
imaged at median 17 hours), temperature in ischemic brain was higher than in normal-appearing brain on admission (38.61C-core,
37.91C-contralateral hemisphere, P¼ 0.03) but both were equally elevated by 5 days; both were higher than tympanic temperature.
Ischemic lesion temperature was not associated with NIHSS or 3-month functional outcome; in contrast, higher contralateral
normal-appearing brain temperature was associated with worse NIHSS, infarct expansion and poor functional outcome, similar to
associations for tympanic temperature. We conclude that brain temperature is higher than body temperature; that elevated
temperature in ischemic brain reﬂects a local tissue response to ischemia, whereas pyrexia reﬂects the systemic response to stroke,
occurs later, and is associated with adverse outcomes.
Journal of Cerebral Blood Flow & Metabolism advance online publication, 10 April 2013; doi:10.1038/jcbfm.2013.52
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INTRODUCTION
Pyrexia occurs commonly in the ﬁrst few days after acute ischemic
stroke1–4 and is associated with severe stroke, large infarcts,
neurologic deterioration, and poor functional outcome.1–11 It is
unclear whether pyrexia is associated with poor functional
outcome through its association with severe stroke (i.e., simply
because pyrexia is a consequence of severe stroke) or if pyrexia
accelerates ischemic brain damage and hence worsens functional
outcome independently, or both. There is little information on brain
temperature after ischemic stroke in patients or how temperature
in the ischemic or normal brain relates to pyrexia. Nonetheless,
there is increasing interest in the potential of hypothermia to
reduce brain damage and improve stroke outcome.2,12,13
Brain temperature is difﬁcult to measure. Invasive probes only
sample a restricted local volume of tissue so cannot assess
temperature distribution between abnormal and normal tissue, is
only possible in patients with severe stroke who justify invasive
monitoring, and opening the skull may itself alter temperature
dynamics. Brain temperature can be measured noninvasively
using magnetic resonance (MR) spectroscopy of the hydrogen
atom (1H MR spectroscopy (MRS))14 which, when combined with
spectroscopic MR imaging (MRI), provides data on temperature
distribution across the brain, including the ischemic and normal
tissue, with sufﬁcient reliability for group comparisons.15,16
Using 1HMRS and diffusion-weighted imaging (DWI),17,18 we
found previously in 40 patients with acute ischemic stroke that
temperature in the DWI-deﬁned ischemic tissue was elevated,
particularly in the potential penumbral tissue, within 24 hours of
stroke. However, we found no clear association between early
temperature elevation in ischemic brain and stroke severity17
although ischemic lesion temperature was higher in larger
lesions.18 We only had body temperature measured at the time
of MRI: at that time point, brain temperature was higher than body
temperature, and only one of the 40 patients was pyrexial within
24 hours of admission.18
The few other studies of brain temperature in acute stroke in
patients used invasive brain temperature probes inserted at
craniotomy: these studies found higher brain lesion than tympanic
temperature,19 consistent with our ﬁndings using MRS, but were
only able to include small numbers of patients who all had severe
stroke and were unable to sample a wide range of brain tissues.
No other data on temperature in normal and abnormal brain soon
after ischemic stroke or at later times have been published since
our original observations.17,18
Our previous study17,18 lacked detailed information on body
temperature so was unable to provide reliable information on
associations with temperature in ischemic or normal brain or
with outcome. We recently reported detailed body temperature
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measurements in a new cohort of 44 patients up to 7 days after
stroke,11 showing that it was peak rather than admission
temperature, occurring at 1.5 to 2 days after stroke, that was
related to stroke severity and more closely associated with poor
functional outcome. We hypothesized that the temporal proﬁle
and associations with clinical variables would be different for
temperature in ischemic brain and in the body after stroke and
that temperature in contralateral normal (CNL) brain would have
similar proﬁle and associations with body temperature. Therefore,
we compared brain temperature measured twice in the ﬁrst week
after stroke with serial tympanic temperature measurements to
determine the relationship between temperature in ischemic and
CNL brain, body temperature proﬁle and early and late clinical
(neurologic, functional) and imaging-derived outcomes.
MATERIALS AND METHODS
Patient Recruitment
We prospectively recruited patients with acute ischemic stroke admitted to
our hospital acute stroke service. The study was approved by the Scotland
A Multicentre Research Ethics Committee (06/MRE00/119) and written
informed consent was obtained from the patient or assent from their
relatives. Patients who had metal inserts or were MR incompatible for other
medical reasons, or who received thrombolytic treatment, or who turned
out to have intracerebral hemorrhage or a stroke mimic, were excluded.
On admission, a trained stroke physician measured stroke severity using
National Institutes of Health Stroke Scale (NIHSS) and determined stroke
subtype by the Oxfordshire Community Stroke Project classiﬁcation.20 The
stroke onset was deﬁned as the time when symptoms or signs were ﬁrst
noticed by the patient or an observer. National Institutes of Health Stroke
Scale was assessed again at 120 hours after stroke and modiﬁed Rankin
Score (mRS) was assessed at 3 months, blinded to imaging and
temperature measurements.
Body Temperature Measurement
We recorded body temperature from the tympanic membrane using a First
Temp Genius digital aural thermometer (Pearson Surgical, Sylmar, CA,
USA), taken four hourly from arrival at hospital, additionally at the time of
the ﬁrst 1HMRS scan, up to 120 hours or the second brain 1HMRS scan
whichever came later (see below). We recorded from both ears in 11
patients to test side-to-side variation and found none. Thereafter, we
recorded from the uppermost ear.21 Tympanic thermometry is considered
as reliable for serial readings22 shows the least variation with age com-
pared with axillary, rectal and oral thermometry23 and is widely used in
clinical practice. We deﬁned pyrexia as tympanic temperature X37.51C as
in previous studies.24 We searched for causes of pyrexia including any
evidence of infection, deep vein thrombosis or surgical intervention as well
as recording paracetamol and antibiotic use. Details of tympanic temp-
erature measurements, proﬁles, proportions becoming, and clinical factors
associated with pyrexia in these patients were published recently.11
MR Diffusion Imaging and Spectroscopy Techniques
Patients underwent MRI as soon as possible after stroke but within a
maximum of 26 hours from onset. This time window allowed for inclusion
of patients who were admitted overnight or late the preceding afternoon,
as the research MR scanner only operated during normal daytime working
hours. Follow-up MRI was performed between 3 and 7 days after stroke
(subacute). We obtained axial T2-weighted fast spin-echo and ﬂuid
attenuated inversion recovery imaging, axial diffusion tensor imaging
(DTI), point resolved spectroscopy (PRESS)-localized 1HMRS on admission
and subacutely. All MR data were obtained on a GE Signa HDX 1.5T
(General Electric, Milwaukee, WI, USA) scanner with self-shielding gradients
(33mT/m maximum) and a ‘birdcage’ quadrature head coil on the same
scanner as described previously.17,18,25 Diffusion tensor imaging was
performed with ﬁeld-of-view 240 240mm, 15 axial slices of thickness
5mm, slice gap 1mm, acquisition matrix 128 128, echo time 97.4ms,
repetition time 10 seconds and diffusion sensitizing gradients with scalar
b-values of 1,000 s/mm2 applied in six noncollinear directions. The PRESS-
localized 1HMRS was performed with ﬁeld-of-view 320 320mm, slice
thickness 10mm, acquisition matrix 24 24, echo time 145ms and
repetition time 1,000ms. We used three-pulse chemical shift selective
water suppression and shimming, optimized on the slice of interest.
Additional saturation bands were placed around the PRESS box to
minimize lipid contamination. The 1HMRS voxel grid was carefully centered
on the slice showing the maximum ischemic lesion extent on DTI and
placed within brain to avoid contamination of the spectra by lipid signal
from bone marrow or subcutaneous tissue, but to include as much of the
lesion and ipsilateral and contralateral brain as possible. Each 1HMRS data
set tookB9 minutes to acquire, the data being effectively ‘averaged’ over
this period.
1HMRS Brain Thermometry
The methodology of 1HMRS brain thermometry in stroke patients and its
validity have been described and discussed in detail previously.15,17,18
Brieﬂy, cerebral temperature for each voxel was calculated from the
relative chemical shifts of water and N-acetyl aspartate. Temperature-
dependent changes in hydrogen bonding cause the water chemical shift
to vary linearly with temperature at 0.01 p.p.m. per degree,14,16 while the
chemical shift of N-acetyl aspartate is independent of temperature. Both
chemical shifts are essentially independent of pH.26 N-acetyl aspartate and
water peaks were identiﬁed by their characteristic appearances at echo
time 145ms. The metabolite concentration quantiﬁcation accounts for coil
loading (using the scanner’s radiofrequency transmitter gain) and receiver
gain thus enabling intersubject and intrasubject comparison of individual
metabolite concentrations and temperatures. We previously found that
coil uniformity was very good across an axial slice near the center of the
coil (unpublished). We quantiﬁed metabolites in ‘institutional units’ (i.u.).
Tissue Classiﬁcation and Estimation of Tissue Metabolite
Concentrations
We processed image and temperature data as previously. We coregistered
1HMRS and DTI data using a 3D afﬁne transformation and visualized the
multivoxel MR spectroscopy grid superimposed onto the corresponding
admission DTI using in-house software. Spectroscopic images were
interpolated to a 32 32 matrix yielding 1,000mm3 voxels and all
processing was performed on a voxel-by-voxel basis after setting the
residual water signal in each voxel to a standard chemical shift of
4.70 p.p.m. All spectroscopic data were modeled in the time domain by ﬁve
Gaussian components (corresponding to choline, creatine, N-acetyl
aspartate containing compounds and the two components of lactate)
using the AMARES (Advanced Method for Accurate Robust and Efﬁcient
Spectral Fitting) algorithm within the MRUI (Magnetic Resonance User
Interface) package (http://www.mrui.uab.es/mrui). We transformed the
data to spectra for display and visual quality control. We discarded spectra
with ﬁtted line widths o1Hz or 410Hz, metabolite peaks 40.1 p.p.m.
offset from their expected values, from voxels lying on the edges of the
PRESS excitation region or from voxels containing 420% cerebrospinal
ﬂuid. We perform weekly spectroscopy quality assurance on our scanner
with appropriate phantoms to maintain scanner stability.
Maps of the average DWI and apparent diffusion coefﬁcient signal were
obtained from the six DWI images acquired for each slice. We super-
imposed the 1HMRS acquisition grid onto the DWI image to classify each
grid voxel on the admission and follow-up DTI image as previously
described,17,18 blind to temperature, clinical data, and baseline/follow-up
imaging as appropriate using software written in-house.27 Based on the
DWI appearance, each grid voxel was classiﬁed as: deﬁnitely abnormal
(DAL) corresponding to clearly hyperintense tissue on DTI representing
ischemic lesion core; possibly abnormal (PAL) corresponding to minimally
hyperintense tissue on DTI at the edge of the ischemic lesion; a one voxel-
thick rim of DTI-healthy looking tissue located immediately outside the
lesion (PALþ ); ipsilateral normal (INL) corresponding to INL tissue on DTI
located outside PALþ voxels; and CNL corresponding to normal tissue
(Figure 1) in the opposite hemisphere. We considered the PAL and PALþ
voxels to correspond to the ‘potential penumbral tissues’ as previously.18
To quantify ischemic lesion growth, we classiﬁed the DTI lesion on
admission and at 3 to 7 days after stroke using a validated qualitative
stroke lesion classiﬁcation that distinguishes changes in lesion size due to
an increase in lesion extent (scale of 1 to 8 in the middle cerebral artery
territory) from changes due to lesion swelling (scale of 1 to 6).28 It also
classiﬁes lesions in the other arterial territories on a similar basis. This rating
method has high observer reliability, and excellent discrimination of lesion
extent.29 A trained observer rated the lesion extent and swelling on the DTI
and ﬂuid attenuated inversion recovery images at admission and 3 to 7
days, independently and blind to clinical, outcome, and temperature data.
Change in lesion extent was indicated by a change in one point or more on
the rating scale and by change in DTI lesion volume. The DTI lesion volume
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was measured by a trained observer manually outlining the hyperintense
tissue on each slice on which it was visible in Analyze (Mayo Clinic,
Rochester, MN, USA).
Statistical Analysis
All statistical comparisons were performed with nonparametric tests unless
there were 20 or more observations and the variances were equal
(variances were compared using Leven’s test). We compared temperatures
between ﬁve brain tissue subregions (DAL, PAL, PALþ , INL, and CNL) and
between brain regions and body temperature using Kruskal–Wallis and
Mann–Whitney U-tests. Not all patients contributed all tissue subregions
but all available data were used (e.g., in a patient with a large lesion the
MRS grid might not include INL brain although CNL brain was included).
The presence or absence of lesion growth was compared with brain
temperatures on admission by brain subregion (Wilcoxon test). We
compared patients with good versus poor outcome at 3 months by
dichotomizing the mRS score into 0-2, ‘independent’, versus 3-6,
‘dependent or dead’ with their admission subregional brain temperatures
(Mann–Whitney U-test). The correlation between temperatures of brain
subregions and NIHSS at admission was tested with the Spearman method.
Where data were missing, we performed the analysis including all patients
and separately with just those patients contributing data to all
components of the analysis to test if there was any difference resulting
from missing data. Finally, we performed multiple logistic regression
including age, NIHSS, and CNL temperature (as the tissue class with the
most available data) on 3-month mRS.
RESULTS
We initiated recruitment on 48 patients but 2 with an intracerebral
hemorrhage, 1 with complex migraine and 1 with functional limb
weakness were excluded, leaving 44 patients with ischemic stroke.
Four patients were unable to tolerate the admission MRI and
produced no images, leaving 40 patients with initial imaging and
body temperature data for analysis. No patients received licensed
alteplase treatment (within 3 hours of stroke at that time); three
patients were randomized to the control group in a trial of
alteplase within 6 hours of ischemic stroke.
The mean age was 72 years, range 37 to 88, including 19 males
and 21 females. There were 12 total anterior circulation, 17 partial
anterior circulation, 5 posterior circulation, and 6 lacunar
syndromes on the Oxfordshire Community Stroke Project
classiﬁcation.20 The mean NIHSS on admission was 10, median 7,
range 1 to 28. The median DTI ischemic lesion volume was 15.3mL
(min 0.6, max 489mL) at baseline and 23.3mL (min 1.4, max
621mL) on follow-up scanning at median 5 days after stroke. At 3
months, 17 patients were alive and independent (mRS 0-2) and 23
patients were dependent or dead (mRS 3-6).
Body Temperature Proﬁles
All patients were normothermic on admission, the median
admission tympanic temperature being 36.41C, (min 361C, max
36.71C) measured at median 4.5 hours (min 1, max 19 hours) after
stroke. The median peak tympanic temperature was 37.31C (SD
0.55; min 361C, max 38.41C) and was recorded at median 36 hours
(1.5 days) after stroke (min 2, max 110 hours).11
Twelve patients became pyrexial during the recording period,
at a median time of 29 hours (1.2 days, range 9 to 71 hours)
after stroke (details provided in Karaszewski et al.11). Patients
who became pyrexial had more severe stroke on admission
(NIHSS 12 versus nonpyrexial 6.5, P¼ 0.04), a larger DWI lesion
volume on admission (58.8 versus apyrexial 6.5mL, P¼ 0.008) and
reached a higher peak body temperature (38.81C versus apyrexial
36.81C, Po0.001) than patients who remained apyrexial, but there
was no difference in age (71.9 versus 71.9) or time to peak tempe-
rature (40.2 versus apyrexial 49.8 hours, Table 1). Note that in some
patients, the admission temperature was also the peak tempera-
ture or the peak temperature occurred soon after admission.
Figure 1. Example of voxel grid categorization according to tissue
appearance on diffusion tensor imaging (DTI). CNL, contralateral
normal brain; DAL, definitely abnormal tissue; INL, ipsilateral normal
brain; PAL, possible abnormal tissue; PALþ , tissue one voxel thick
immediately outside the lesion.
Table 1. Characteristics of patients who became pyrexial and who
remained apyrexial
No pyrexia
(n¼ 28)
Pyrexia
(n¼ 12)
Sex
Male 15 4
Female 13 8
Mean age (years) 71.9 (11.7) 71.9 (11.3) P¼ 0.990
Stroke severity
Admission NIHSS
(median, IQR)
6.5 (3–10) 12 (5–18) P¼ 0.038
DWI lesion volume
(median)
6,521 58,052 P¼ 0.008
(MWU)
Body temperature
Peak (mean 1C, SD) 36.8 (0.4) 37.8 (0.3) Po0.001
Time to peak (mean
hours after onset, SD)
49.8 (24.5) 40.2 (25.5) P¼ 0.262
Outcome
mRS p2 15 2 w2¼ 3.5
mRS X3 13 10 P¼ 0.061
DWI, diffusion-weighted imaging; IQR, interquartile range; mRS, modified
Rankin Scale; MWU, Mann–Whitney U-test; NIHSS, National Institute of
Health Stroke Scale; SD, standard deviation.
Pyrexia was any body (aural) temperature measurement X37.51C during
the recording period.
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Brain Temperatures
The median time from stroke onset to admission MRI was 17 hours
(range 3 to 26 hours): nine patients were imaged o6, three
between 6 and 12, 14 between 12 and 18 hours, and 14 between
18 and 26 hours after stroke. Data available for some of the
analyses of brain temperature were further reduced due to
impaired spectra (patient movement or poor shimming) or no
follow-up imaging (early patient discharge or too ill/died), but all
available data were used in each analysis. Therefore, brain
temperature data were available for a total of 35 patients at each
time point of whom 30 individual patients provided brain
temperature measures at both time points and 10 provided brain
temperature measures at one or other time point but not both.
At the time of the admission MRI, the median temperatures of
lesion core (DAL, 38.61C) and potential penumbra (PAL, 38.31C,
PALþ , 38.71C) were higher than temperatures of INL (37.61C) and
CNL brain (37.91C: abnormal versus normal tissues, P¼ 0.03; CNL
versus INL, Po0.05; Figure 2). Thirty-seven patients underwent
follow-up MRI, performed at median 5 days (range 3 to 7 days)
after stroke, of whom 35 contributed brain temperature data. The
temperature in DAL (38.81C), PAL (38.11C), and PALþ (38.11C)
tissue and in DWI-normal tissues (ipsilateral 38.41C, contralateral
38.51C) were all similar (P¼ 0.3; Figure 2).
Brain and Body Temperature Comparison
On admission MRI, all brain regions, whether DWI-abnormal or
normal appearing, were hotter than concurrently measured
tympanic temperatures (mean 36.61C, Po0.001, 0.032 and 0.001,
respectively) (Figure 3A). On follow-up MRI, all brain regional
temperatures remained hotter than tympanic temperature measured
concurrently (mean 36.31C, Po0.001 all comparisons, Figure 3B).
On admission MRI, the temperature in the INL or CNL-appearing
brain did not differ in the 12 patients who became pyrexial from
that in 28 who remained apyrexial, either on the baseline
(ipsilateral, pyrexial 37.61C versus apyrexial 37.41C, P¼ 0.9;
contralateral, pyrexial 37.31C versus apyrexial 37.81C, P¼ 0.4) or
the follow-up scan (ipsilateral, pyrexial 38.41C versus apyrexial
38.41C, P¼ 0.9; contralateral, pyrexial 38.81C versus apyrexial
38.41C, P¼ 0.5), Figure 4.
Admission brain temperature, early and late imaging, and clinical
outcomes
Between admission and follow-up imaging, 11 patients showed
lesion expansion and 27 patients had either no change or a
reduction in DWI lesion size (2 patients did not have a follow-up
scan). Mean temperature of CNL tissue on admission was higher in
patients whose lesion grew (38.31C) than in those whose lesion
did not expand (37.71C, P¼ 0.014) at follow-up. There was no
Figure 2. Temperatures (mean of patients’ means shown) (1C) of
ischemic and normal-appearing brain at admission to hospital and
follow-up at around 5 days after stroke. CNL, contralateral normal
brain; CSI, chemical shift imaging; DAL, definitely abnormal tissue;
INL, ipsilateral normal brain; PAL, possible abnormal tissue; PALþ ,
tissue one voxel thick immediately outside the lesion.
Figure 3. Brain and body temperature (A) on admission and (B) at
median 5 days after stroke. CI, confidence interval.
Figure 4. Tympanic temperature and temperature in ipsilateral and
contralateral normal-appearing brain tissue in patients who became
pyrexial at any time within the first 7 days after admission and those
who did not. CI, confidence interval.
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difference in temperatures between the two groups in the
remaining brain subregions (Table 2).
National Institutes of Health Stroke Scale on admission was
associated with contralateral hemisphere brain temperature
(r¼ 0.42, P¼ 0.01) but there were no associations with tempera-
tures in any other brain regions (Table 2). Between admission and
follow-up imaging at median 5 days, the NIHSS improved by four
or more points or reached zero in 14 patients, did not change by
43 points in 17 patients, or worsened by 4 or more points in
4 patients. On admission, mean temperatures of DAL, PAL, and INL
tissue were higher in patients whose NIHSS worsened or did not
change by 5 days than in those whose NIHSS improved (Po0.05)
but temperature in CNL tissue on admission was not associated
with change in NIHSS by 5 days.
At 3 months, 17 patients achieved good (mRS 0-2) and 23 patients
achieved poor (mRS 3-6) functional outcomes. Higher admission
temperatures in CNL tissue were associated with poor 3-month
functional outcome (Po0.05) but there were no associations
between temperature in the ischemic lesion (DAL, PAL, or PALþ )
and 3-month functional outcome. However after correcting for
age and NIHSS on multivariable logistic regression, CNL tempera-
ture was no longer associated signiﬁcantly with mRS 3-6.
DISCUSSION
Soon after acute ischemic stroke, higher temperatures in
contralateral DWI-normal appearing brain, but not in ischemic
brain, are associated with worse admission NIHSS, lesion expan-
sion by 5 days and poor 3-month functional outcome. This
conﬁrms our hypothesis, based on earlier work in 40 patients18
but now including data on 80 patients, that soon after ischemic
stroke, temperatures in ischemic lesion core and potential
penumbral tissues are hotter than ipsilateral or contralateral
DWI-normal-appearing brain. Neither study found associations
between ischemic brain temperature and admission stroke
severity. The associations between CNL temperature and clinical
ﬁndings parallel those found for tympanic temperature in the
same patients11 and that others have found for body temperature
in other studies1–10 summarized in Karaszewski et al.11 The
difference in the pattern of brain temperature elevation in the
ischemic lesion, combined with the different associations with
clinical and imaging features, suggests that the mechanism(s) for
early temperature elevation in ischemic brain are different to
those which elevate temperature in normal-appearing brain and
cause pyrexia. This leads to several important conclusions:
(a) The elevated temperature in ischemic tissue is not directly
related to body temperature and possibly not to progression
of brain injury, and appears to have a different mechanism to
that of body and normal-appearing brain temperature;
(b) that body temperature elevation after ischemic stroke occurs
secondary to the systemic (presumably inﬂammatory)
response to brain injury and is reﬂected in temperature in
normal-appearing brain. Hence, body temperature takes time
to rise, peaks at around 1 to 2 days after stroke onset, and (as
summarized previously11) patients are usually apyrexial within
the ﬁrst few hours of stroke. None of the present study
patients was pyrexial on admission; 12 became pyrexial up to
5 days after stroke. This interpretation is also consistent with
the observed relationship between plasma inﬂammatory
markers and temperature proﬁles in normal-appearing but
not in ischemic brain, reported previously30;
(c) and that brain temperature is consistently higher than body
temperature, perhaps due to the heat byproducts of the
metabolically very active brain.
The early temperature elevation in ischemic brain has several
explanations. It may reﬂect continued cell metabolism generating
heat but inadequate blood ﬂow to remove the heat and cool the
tissue, or activation of mechanisms intended to counteract
ischemic damage by dissipating energy, that cannot be used by
ischemic cells, as heat. For example, genes that control
mitochondrial oxidative activity like uncoupling proteins mediate
tolerance to ischemic insults in experimental models31 and
uncoupling proteins single-nucleotide polymorphisms are
associated with risk of cardiovascular disease in humans.32
This study has limitations. The relatively small sample size (40)
reﬂects the difﬁculty in undertaking complex MRI studies in
patients with moderate to severe acute stroke. The absence of
other studies of brain temperature after stroke and the very few
using spectroscopy is testament to this difﬁculty. Nonetheless, we
have doubled the existing literature: data on 80 patients in two
independent studies show the same brain temperature pattern
after ischemic stroke. In both current and previous studies,17,18
temperatures across the brain were measured at a relatively wide
range of times (baseline up to 26 hours after stroke), many within
the ﬁrst 12 hours. However, within the ﬁrst 24 hours, many
pathologic processes occur in ischemic brain33,34 that are likely
to inﬂuence local heat production and dissipation. However, the
comparison of ischemic with nonischemic brain and body
temperature is valid as each patient acted as their own control.
None of the patients received alteplase: therefore, these results
reﬂect the ‘natural history’ of nonthrombolysis-treated ischemic
stroke. It is possible that alteplase, by restoring tissue perfusion, will
alter ischemic tissue temperature proﬁles, or by reducing stroke
severity and infarct extent will alter body temperature proﬁles and
reduce pyrexia. The work should be repeated in thrombolysis-
treated patients. We only performed limited multivariate statistical
modeling as the sample size precluded reliable results.
Methodological limitations related to 1HMRS thermometry,
discussed previously,15,17,18 are worth reiterating. Calibration, in
Table 2. Comparison between brain temperature (1C) on admission
and ischemic lesion expansion by median 5 days after stroke, change
in NIHSS from admission to 5 days after stroke, and functional
outcome at 3 months
Admission brain
temperatures (1C)
DAL PAL PALþ INL CNL
Ischemic lesion expansion by 3–5 days
Lesion
expansion
38.8 (3) 37.9 (7) 38.0 (3) 37.1 (6) 38.3 (10)
No lesion
expansion
38.7 (8) 38.0 (16) 38.8 (13) 37.7 (21) 37.7 (23)
P value 0.54 0.32 0.45 0.13 0.01
Change in NIHSS from admission to 120 hours after stroke
No
improvement
in NIHSS
39.3 (6) 38.8 (11) 38.4 (9) 38.0 (15) 38.1 (18)
Improvement
in NIHSS
37.7 (4) 37.5 (12) 39.1 (8) 37.3 (13) 37.9 (15)
P value 0.01 0.04 0.37 0.04 0.18
Functional outcome at 3 months
Poor outcome
mRS 3-6
38.7 (10) 38.6 (13) 38.9 (8) 37.6 (13) 38.2 (19)
Good
outcome mRS
0-2
38.8 (1) 37.7 (11) 38.6 (9) 37.6 (16) 37.6 (16)
P value 0.91 0.31 0.96 0.59 0.002
CNL, contralateral normal brain; DAL, definitely abnormal tissue; INL,
ipsilateral normal brain; PAL, possible abnormal tissue; PALþ , tissue one
voxel thick immediately outside the lesion; mRS, modified Rankin Scale;
NIHSS, National Institute of Health Stroke Scale.
Number in brackets is number of patients in each category. Temperatures
are 1C.
Bold values highlight differences that are significant.
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this and our previous work, currently assumes that brain
temperature in healthy subjects is 371C. However, some data
suggest that normal brain temperature may be slightly higher; in
volunteer studies, we ﬁnd temperatures of 381C even with this
calibration (unpublished data). Unfortunately, there is no
reference standard. True temperatures may be slightly different
to the values given by 1HMRS thermometry, but within an
individual they are comparable. More studies are required to
examine important factors like temperature variation in gray and
white matter, effect of tissue water content, and stage in
infarction.
This study has strengths. MR thermometry enables simulta-
neous measurement of tissues across the ischemic lesion to
normal brain. Other studies have measured brain temperatures
using invasive probes, but this restricts measurement to a small
volume of brain, of uncertain location, affects brain temperature
through breaching the skull and can only be used when invasive
monitoring is justiﬁed clinically, i.e., in the severe strokes. We
performed all assessments in standardized ways, blinded all
analyses. We used operational deﬁnitions of ischemic lesion core
and potential penumbral tissues.18 We used validated software to
assign tissue classiﬁcations, with good rater reliability and biologic
relevance.27 Our sample, though small, was representative of
hospital admitted patients.
Why should body temperature be related to initial stroke
severity, and why should body temperature elevation adversely
inﬂuence lesion growth and functional outcome? Experimental
data suggest that higher temperatures not only accelerate
ischemic damage but also accelerate opening of the blood–
brain barrier.35 If these observations also apply in humans,35 then
higher temperatures in contralateral brain could inﬂuence lesion
progression and worsen outcome by promoting blood–brain
barrier opening in the ischemic tissue, exacerbating tissue
swelling, worsening tissue capillary blood ﬂow, leading to
recruitment of more tissue into the ischemic lesion, lesion
expansion and worse functional outcome.36
If the foregoing interpretation is correct, then therapeutic
hypothermia might work by cooling nonischemic tissue, prevent-
ing blood–brain barrier opening, reducing peri-infarct damage,
and preventing infarct growth, but might not have much
inﬂuence on the primary ischemic core tissue. Hence, the
combination of thrombolysis to salvage ischemic but viable
cells,37 plus hypothermia to reduce blood–brain barrier opening,
tissue edema, and recruitment of peri-infarct tissue into the
infarct, might be doubly effective in improving functional
outcome. Thrombolysis might also enhance hypothermia because
the act of restoring blood ﬂow to the ischemic cells could also
help to remove the excess heat generated. Thus, therapeutic
hypothermia might be beneﬁcial even if started 46 hours after
stroke and even modest reductions of only 11C or 21C might
protect at risk tissue from progression to permanent damage or
recruitment of initially not at risk tissue into the infarct. Further
trials of hypothermia38 should be encouraged to test these
hypotheses. If our observations are correct, then body
temperature is likely to be the more relevant measure for
clinical outcomes.
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